ArticleBJC reports2026
Urinary volatilomics using liquid-liquid extraction and gas chromatography-mass spectrometry (GC-MS) combined with machine learning algorithms as a tool for diagnosis and surveillance of urothelial bladder cancer.
Article in BJC reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundBladder cancer is the 11th most common cancer in the United Kingdom, with approximately 10,500 new cases annually. Diagnosis and surveillance typically involve cystoscopy, an expensive, time-consuming, and uncomfortable procedure which has encouraged efforts to identify biomarkers, particularly in urine, given its direct contact with malignant tissue.
methodsUrine collected from 100 participants (50 bladder cancer patients, 50 controls) was subjected to solvent extraction followed by gas chromatography-mass spectrometry (GC-MS) to determine potential volatile and semi-volatile biomarkers. The results were analysed using classical univariate statistics and machine learning methods. Five machine learning algorithms were evaluated, with recursive feature elimination (RFE) identifying optimal biomarker panels.
resultsMachine learning with XGBoost achieved area under the receiver operating characteristic curve (AUROC) of 0.869 (95% CI: 0.740-0.988), representing a significant improvement over the classical statistical approach (AUROC 0.752). An 8-metabolite panel achieved balanced sensitivity and specificity of 85%, or 95% sensitivity with 70% specificity when optimised for screening.
conclusionsThe findings indicate that solvent extraction of urine shows promise for isolating putative biomarkers of bladder cancer. Employing machine learning achieved diagnostic accuracy potentially suitable for clinical deployment as a non-invasive bladder cancer detection tool.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.